ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

October 27, 2006

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

December 26, 2003

NY Attorney General Sues Drug Companies Over Cancer Drug Pricing Deals

February 14, 2003

Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.

November 12, 2004

HHS Reports Some Gains In Reducing Health Disparities

February 8, 2002

NCCN Guidelines Retain Avastin For Breast Cancer

October 22, 2010